Relmada Therapeutics Inc (RLMD)

0.4783 +0.04 (+8.70%) USD  |  NASDAQ  |  Jan 07, 16:00
0.47 -0.01 (-1.74%) After-Hours: 16:13
More

Relmada Therapeutics Research and Development Expense (Annual): 54.81M for Dec. 31, 2023

Research and Development Expense (Annual) Chart

View Research and Development Expense (Annual) for RLMD.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Annual) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Annual) Range, Past 5 Years

View Research and Development Expense (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Annual) Benchmarks

View Research and Development Expense (Annual) Benchmarks
Start Trial
Eli Lilly and Co 9.313B
Equillium Inc 37.04M
Sensei Biotherapeutics Inc 18.30M
NovaBay Pharmaceuticals Inc 0.068M
Palatin Technologies Inc 22.40M